The burgeoning field of diabetes therapy has seen tremendous advancements with the emergence of novel incretin mimetics like semaglutide and tirzepatide. These medications demonstrate promising outcomes in managing blood sugar levels, impacting the treatment paradigm for type 2 diabetes. However, their deployment on a global scale requires careful